566TiP A first-in-human study of NUC-7738, a ProTide transformation of 3’-deoxyadenosine, in patients with advanced solid tumours (NuTide:701)
Sarah P. Blagden(Churchill Hospital), Ruth Plummer(National Health Service), Michelle Myers(Nucana (United Kingdom)), Zhuang Boh(Edinburgh Cancer Research), Farasat Kazmi(University of Oxford), Francesca Aroldi(Churchill Hospital), Noor Md Haris(Freeman Hospital), Stefan N. Symeonides(Edinburgh Cancer Research)
Cited by 0
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406